Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 3/2018

Content (15 Articles)

Review

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Jürgen C. Becker, Andreas Stang, Axel zur Hausen, Nicole Fischer, James A. DeCaprio, Richard W. Tothill, Rikke Lyngaa, Ulla Kring Hansen, Cathrin Ritter, Paul Nghiem, Christopher K. Bichakjian, Selma Ugurel, David Schrama

Original Article

Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model

Yi Zhang, Zuqiang Liu, Xingxing Hao, Ang Li, Jiying Zhang, Cara D. Carey, Louis D. Falo, Zhaoyang You

Original Article

Prophylactic DNA vaccine targeting Foxp3+ regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model

Afshin Namdar, Reza Mirzaei, Arash Memarnejadian, Roobina Boghosian, Morteza Samadi, Hamid Reza Mirzaei, Hamid Farajifard, Mehdi Zavar, Kayhan Azadmanesh, Shokrollah Elahi, Farshid Noorbakhsh, Abbas Rezaei, Jamshid Hadjati

Original Article

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

David Briere, Niranjan Sudhakar, David M. Woods, Jill Hallin, Lars D. Engstrom, Ruth Aranda, Harrah Chiang, Andressa L. Sodré, Peter Olson, Jeffrey S. Weber, James G. Christensen

Original Article

Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor

Bai-Le Zuo, Bo Yan, Guo-Xu Zheng, Wen-Jin Xi, Xiao Zhang, An-Gang Yang, Lin-Tao Jia

Original Article

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann

Original Article

Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737

Theresa Noll, Susanne Schultze-Seemann, Irina Kuckuck, Marta Michalska, Philipp Wolf

Original Article

Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome

Larisa J. Geskin, Oleg E. Akilov, Soonyou Kwon, Michael Schowalter, Simon Watkins, Theresa L. Whiteside, Lisa H. Butterfield, Louis D. Falo Jr.

Original Article

The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases

Yun Wang, Hao-cheng Lin, Ma-yan Huang, Qiong Shao, Zhi-qiang Wang, Feng-hua Wang, Yun-fei Yuan, Bin-kui Li, De-shen Wang, Pei-rong Ding, Gong Chen, Xiao-jun Wu, Zhen-hai Lu, Li-ren Li, Zhi-zhong Pan, Peng Sun, Shu-mei Yan, De-sen Wan, Rui-hua Xu, Yu-hong Li

Original Article

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

Kamiya Mehla, Jarrod Tremayne, James A. Grunkemeyer, Kelly A. O’Connell, Maria M. Steele, Thomas C. Caffrey, Xinyi Zhu, Fang Yu, Pankaj K. Singh, Birgit C. Schultes, Ragupathy Madiyalakan, Christopher F. Nicodemus, Michael A. Hollingsworth

Original Article

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jong Seok Lee

Original Article

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Xu-chao Zhang, Xu Cao, Chun Sun, Zhi Xie, Jian-jun Guo, Jin-ji Yang, Xue-ning Yang, Hang-jun Dai, Su-chun Li, Xin-ran Xu, Yun-xia Zuo, Meng Chen, Hartmut Koeppen, Jing He, Astrid Kiermaier, David Shames, Gang Cheng, Yi-long Wu

Original Article

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

Veronika Bachanova, Dhifaf Sarhan, Todd E. DeFor, Sarah Cooley, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Julie M. Curtsinger, Linda Burns, Daniel J. Weisdorf, Jeffrey S. Miller

Original Article

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

Yusuke Okuma, Tsunekazu Hishima, Jumpei Kashima, Sadamu Homma

ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgements

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine